Listen
METYRAPONE HRA PHARMA (metyrapone), treatment of endogenous Cushing’s syndrome and test for pituitary function
ENDOCRINOLOGY - New medicinal product
Opinions on drugs -
Posted on
Nov 04 2016
Reason for request
Inclusion
Minor improvement in the treatment of endogenous Cushing’s syndrome.
No clinical benefit demonstrated as a dynamic test exploring the function of the hypothalamic-pituitary-adrenal axis.
- METYRAPONE HRA PHARMA has Marketing Authorisation in the treatment of patients with endogenous Cushing’s syndrome, the diagnosis of ACTH deficiency, and the differential diagnosis of ACTH-dependent Cushing’s syndrome.
- The data from clinical studies offer low levels of proof in the treatment of Cushing’s syndrome without any convincing demonstration of benefit in terms of diagnostic performance.
- Metyrapone’s delayed action is short, with a plasma peak reached in 1 hour.
- It forms part of the arsenal of protocols exploring the function of the hypothalamic-pituitary-adrenal axis.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| minor |
- |
| no clinical added value |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
